Radiation therapy advances for treatment of anal cancer

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 8, Issue 1, 2010, Pages 123-129

  Pepek, Joseph M ^a   Willett, Christopher G ^a   Czito, Brian G ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anal cancer; IMRT; Intensity modulated radiation therapy; Radiation; Toxicity

Indexed keywords

CISPLATIN; FLUORODEOXYGLUCOSE; FLUOROURACIL; MITOMYCIN C;

ANUS CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL; DIARRHEA; DISEASE COURSE; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DOSIMETRY; HEMATOLOGIC DISEASE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; PATIENT SAFETY; POSITRON EMISSION TOMOGRAPHY; RADIATION DOSE; RADIATION FIELD; RADIATION INJURY; RADIATION RESPONSE; REVIEW; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE;

EID: 76549116409     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2010.0008     Document Type: Review

References (39)

1. Nigro ND, Vaitkevicius VK, Considine B Jr. Combined therapy for cancer of the anal canal: a preliminary report. Dis Colon Rectum 1974;17:354-356.
2. Flam M, John M, Pajak TF, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 1996;14:2527-2539.
3. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet 1996;348:1049-1054.
4. Bartelink H, Roelofsen F, Eschwege F, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 1997;15:2040-2049.
5. Ajani JA, Winter KA, Gunderson LL, et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA 2008;299:1914-1921.
6. James R, Wan S, Glynne-Jones R, et al. A randomized trial of chemoradiation using mitomycin or cisplatin, with or without maintenance cisplatin/5FU in squamous cell carcinoma of the anus (ACT II) [abstract]. J Clin Oncol 2009;27(Suppl 1):Abstract LBA4009.
7. Bortfeld T, Boyer AL, Schlegel W, et al. Realization and verification of three-dimensional conformal radiotherapy with modulated fields. Int J Radiat Oncol Biol Phys 1994;30:899-908.
8. Burman C, Chui CS, Kutcher G, et al. Planning, delivery, and quality assurance of intensity-modulated radiotherapy using dynamic multileaf collimator: a strategy for large-scale implementation for the treatment of carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1997;39:863-873.
9. Kam MK, Leung SF, Zee B, et al. Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol 2007;25:4873-4879.
10. Ashman JB, Zelefsky MJ, Hunt MS, et al. Whole pelvic radiotherapy for prostate cancer using 3D conformal and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2005;63:765-771.
11. Trautmann TG, Zuger JH. Positron emission tomography for pretreatment staging and posttreatment evaluation in cancer of the anal canal. Mol Imaging Biol 2005;7:309-313.
12. Cotter SE, Grigsby PW, Siegel BA, et al. FDG-PET/CT in the evaluation of anal carcinoma. Int J Radiat Oncol Biol Phys 2006;65:720-725.
13. Winton E, Heriot AG, Ng M, et al. The impact of 18-fluorodeoxyglucose positron emission tomography on the staging, management and outcome of anal cancer. Br J Cancer 2009;100:693-700.
14. Anderson C, Koshy M, Staley C, et al. PET-CT fusion in radiation management of patients with anorectal tumors. Int J Radiat Oncol Biol Phys 2007;69:155-162.
15. Nguyen BT, Joon DL, Khoo V, et al. Assessing the impact of FDG-PET in the management of anal cancer. Radiother Oncol 2008;87:376-382.
16. Mal SK, Welzel G, Hermann B, et al. Can the radiation dose to CT-enlarged but FDG-PET-negative inguinal lymph nodes in anal cancer be reduced? Strahlenther Onkol 2009;185:254-259.
17. Schwarz JK, Siegel BA, Dehdashti F, et al. Tumor response and survival predicted by post-therapy FDG-PET/CT in anal cancer. Int J Radiat Oncol Biol Phys 2008;71:180-186.
18. Stein J, Bortfeld T, Dorschel B, Schlegel W. Dynamic X-ray compensation for conformal radiotherapy by means of multi-leaf collimation. Radiother Oncol 1994;32:163-173.
19. Kachnic L, Winter K, Myerson R, et al. RTOG 0529: a phase II evaluation of dose-painted IMRT in combination with 5-fluorouracil and mitomycin-C for reduction of acute morbidity in carcinoma of the anal canal [abstract]. Int J Radiat Oncol Biol Phys 2009;75(3 Suppl):Abstract S5.
20. Myerson RJ, Garofalo MC, El Naqa I, et al. Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas. Int J Radiat Oncol Biol Phys 2009;74:824-830.
21. Konski A, Garcia M Jr, John M, et al. Evaluation of planned treatment breaks during radiation therapy for anal cancer: update of RTOG 92-08. Int J Radiat Oncol Biol Phys 2008;72:114-118.
22. Roohipour R, Patil S, Goodman KA, et al. Squamous-cell carcinoma of the anal canal: predictors of treatment outcome. Dis Colon Rectum 2008;51:147-153.
23. Constantinou EC, Daly W, Fung CY, et al. Time-dose considerations in the treatment of anal cancer. Int J Radiat Oncol Biol Phys 1997;39:651-657.
24. Huang K, Haas-Kogan D, Weinberg V, Krieg R. Higher radiation dose with a shorter treatment duration improves outcome for locally advanced carcinoma of anal canal. World J Gastroenterol 2007;13:895-900.
25. Ben-Josef E, Moughan J, Ajani J, et al. The impact on overall treatment time on survival and local control in anal cancer patients: a pooled data analysis of RTOG trials 8704 and 9811 [abstract]. Int J Radiat Oncol Biol Phys 2009;75(3 Suppl):Abstract S26.
26. Widder J, Kastenberger R, Fercher E, et al. Radiation dose associated with local control in advanced anal cancer: retrospective analysis of 129 patients. Radiother Oncol 2008;87:367-375.
27. Hughes LL, Rich TA, Delclos L, et al. Radiotherapy for anal cancer: experience from 1979-1987. Int J Radiat Oncol Biol Phys 1989;17:1153-1160.
28. Milano MT, Jani AB, Farrey KJ, et al. Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome. Int J Radiat Oncol Biol Phys 2005;63:354-361.
29. Pepek JM, Willett CG, Clough RW, et al. Intensity-modulated radiation therapy (IMRT) for anal cancer: the Duke University Experience [abstract]. Int J Radiat Oncol Biol Phys 2009;75(3 Suppl):Abstract S267.
30. Mundt AJ, Lujan AE, Rotmensch J, et al. Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies. Int J Radiat Oncol Biol Phys 2002;52:1330-1337.
31. Mundt AJ, Mell LK, Roeske JC. Preliminary analysis of chronic gastrointestinal toxicity in gynecology patients treated with intensity-modulated whole pelvic radiation therapy. Int J Radiat Oncol Biol Phys 2003;56:1354-1360.
32. Baglan KL, Frazier RC, Yan D, et al. The dose-volume relationship of acute small bowel toxicity from concurrent 5-FU-based chemotherapy and radiation therapy for rectal cancer. Int J Radiat Oncol Biol Phys 2002;52:176-183.
33. Tho LM, Glegg M, Paterson J, et al. Acute small bowel toxicity and preoperative chemoradiotherapy for rectal cancer: investigating dose-volume relationships and role for inverse planning. Int J Radiat Oncol Biol Phys 2006;66:505-513.
34. Gunnlaugsson A, Kjellen E, Nilsson P, et al. Dose-volume relationships between enteritis and irradiated bowel volumes during 5-fluorouracil and oxaliplatin based chemoradiotherapy in locally advanced rectal cancer. Acta Oncol 2007;46:937-944.
35. Ellis RE. The distribution of active bone marrow in the adult. Phys Med Biol 1961;5:255-258.
36. Salama JK, Mell LK, Schomas DA, et al. Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience. J Clin Oncol 2007;25:4581-4586.
37. Brixey CJ, Roeske JC, Lujan AE, et al. Impact of intensity-modulated radiotherapy on acute hematologic toxicity in women with gynecologic malignancies. Int J Radiat Oncol Biol Phys 2002;54:1388-1396.
38. Mell LK, Kochanski JD, Roeske JC, et al. Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy. Int J Radiat Oncol Biol Phys 2006;66:1356-1365.
39. Mell LK, Schomas DA, Salama JK, et al. Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2008;70:1431-1437.